Compare ResMed Inc. (RMD) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Ryanair Holdings plc — how do they compare? ResMed Inc. trades at $194.03 (market cap $28.81B), while Ryanair Holdings plc trades at $58.99 (market cap $29.31B). The key difference: ResMed Inc. and Ryanair Holdings plc are close in size by market cap, and Ryanair Holdings plc pays the higher dividend (1.68%). Which is the better fit depends on your goals.
| RMD | RYAAY | |
|---|---|---|
Market Cap | $28.81B | $29.31B |
Sector | Health | Industrials |
52-Week High | $293.73 | $73.82 |
52-Week Low | $182.82 | $53.24 |
Enterprise Value | $27.99B | $26.33B |
Dividend Yield | 1.21% | 1.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
RYAAY trades at $58.80, down 6.03% amid a bearish technical signal. Recent Q1 2027 earnings missed expectations due to lower fares and higher fuel costs, though the company maintains strong profitability with a 13.98% net margin. Analyst consensus remains positive with 62.5% buy ratings, citing long-term advantages despite near-term headwinds from geopolitical tensions and industry volatility.
The outlook is cautious short-term given earnings pressure and technical weakness, but the strong balance sheet and potential industry consolidation offer recovery potential. Key risks include fuel price volatility and competitive fare pressures, while institutional sentiment suggests the sell-off may be overdone for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
